Ubs Group Ag Dia Medica Therapeutics Inc. Call Options Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DMAC
# of Institutions
62Shares Held
5.97MCall Options Held
14.1KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA1.54MShares$8.01 Million0.0% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX650KShares$3.39 Million4.32% of portfolio
-
Geode Capital Management, LLC Boston, MA630KShares$3.29 Million0.0% of portfolio
-
First Manhattan CO New York, NY606KShares$3.17 Million0.01% of portfolio
-
Bleichroeder LP New York, NY382KShares$2 Million0.47% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $138M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...